P rolonged-QT interval and electrocardiographic left ventricular hypertrophy (ECG-LVH) have been associated with adverse outcomes, including all-cause mortality, coronary heart disease, stroke, and sudden cardiac death. [1] [2] [3] [4] [5] Experimental studies have demonstrated that ECG-LVH could alter ventricular conduction and repolarization, [6] [7] [8] [9] which could be reflected as prolonged-QT interval in the resting ECG. Several studies on clinical populations also have shown the common concomitant presence of prolonged-QT and ECG-LVH in patients with hypertension and hypertrophic cardiomyopathy.
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Methods
NHANES is a periodic survey of a representative sample of the civilian noninstitutionalized US population aimed to determine estimates of disease prevalence and health status of the US population. The National Center for Health Statistics of the Center for Disease Control and Prevention Institutional Review Board approved the protocol for NHANES-III. All participants gave written informed consent. Participant characteristics, ECG methodology, and ascertainment of mortality in the NHANES-III have been published elsewhere. 17 Briefly, NHANES-III baseline data were collected during an in-home interview and a subsequent visit to a mobile examination center from 1988 to 1994. The data collected during the in-home interview included demographics and medical history, including smoking status and the use of medications. Blood pressure data were the averaged reading from 3 in-home measurements and 3 mobile center measurements. Hypertension was defined as systolic and or diastolic blood pressure >140/90 mm Hg or taking blood pressure-lowering drugs.
Using the height and weight measured during the visit to mobile examination center, the body mass index was calculated as the weight in kilograms divided by the height in meters squared and obesity was defined as body mass index >30 kg/m 2 . Diabetes mellitus was defined as fasting plasma glucose ≥126 mg/dL, a nonfasting plasma glucose ≥200 mg/dL or concurrent use of antidiabetic medications. Dyslipidemia was defined as self-reported history of high cholesterol or concurrent use of lipid-lowering drugs.
Study Population
The present analysis includes 7506 participants, who had goodquality ECGs showing sinus rhythm and no major intraventricular conduction delay (including complete bundle branch blocks, Wolf Parkinson-White Syndrome, and QRS duration, ≥120 ms) and available mortality data, medical history, medication use, and anthropometric measurements.
Electrocardiography
Standard 12-lead ECG was recorded using a Marquette MAC 12 system (Marquette Medical Systems, Milwaukee, WI) by trained technicians during the visit of participants to a mobile examination center. Computerized automated analysis of the electrocardiographic data was performed with visual inspection of outlier values by a trained ECG technician in a central ECG core laboratory.
QT interval was measured from global QRS-STT complex derived from the standard 12-lead ECG as the interval from the QRS onset to the T-wave offset (end). We used a linear formula for rate-corrected QT as recommended by a task force sponsored by professional organizations. 18 Specifically, we set up a linear regression model with QT interval as the dependent variable and heart rate interval as the independent variable. On the basis of β-coefficient associated with heart rate, the following formula was derived for heart-rate-adjusted QT (QTa): QTa=QT+2.05×(heart rate-60). The application of this formula in the study population effectively made the QT interval rate-invariant (residual slope of regression, 0.006; 95% confidence interval, -0.035 to 0.047; P=0.78). Prolonged-QTa was defined as QT460 ms or longer for women and 450 ms or longer for men as recommended. 18 We decided not to use the traditional Bazett formula to calculate heart-rate-corrected QT in this study. This is to comply with the current recommendations of ECG interpretation, which explicitly discourage using Bazett formula because of its inability to eliminate the correlation between QT and heart rate appropriately. 18 Noteworthy, Bazett correction formula did not eliminate the dependence of QT on heart rate when we applied it to our study population (residual slope of regression of 0.896; 95% confidence interval, 0.854-0.939; P<0.0001), which accord with the concerns about using it.
ECG-LVH was defined using Cornell voltage criteria (RaVL and SV3, >2800 μV for men and >2000 μV for women). 19 Cornell voltage is one of the most commonly used ECG-LVH criteria that have been shown to have a better diagnostic and prognostic performance when compared with other ECG-LVH criteria. 20 
Mortality Assessment
NHANES-III participants have been followed up for mortality through December 31, 2006. The method of probabilistic matching was used to link NHANES-III participants with the National Death Index. Matching was based on 12 identifiers for each participant, including Social Security number, sex, and date of birth. Up to our knowledge, this method captured all the deaths occurred in our sample until the end of follow-up in 2006.The follow-up period for each study participant was calculated as the interval between their NHANES-III examination and the date of death or December 31, 2006, whichever occurred first.
Statistical Analysis
Frequency distributions of all variables were first inspected to identify anomalies and outliers possibly caused by measurement artifacts. Continuous variables were described by their mean and SD and categorical variables as proportions (percentage). Characteristics of participants were examined and compared across categories stratified by ECG-LVH and prolonged-QTa status.
The prevalence of prolonged-QTa and ECG-LVH, isolated and in combination, and the mortality rate (per 1000 person-years) in each group was calculated.
The effect of prolonged-QTa and ECG-LVH on each other in terms of their association with all-cause mortality was assessed in 2 ways. First, using multivariable Cox proportional hazard models, we examined the associations between prolonged-QTa and ECG-LVH, in isolation and combined, with the risk of mortality. In these models, different combinations of ECG-LVH and prolonged-QTa were used as 1 categorical variable with 4 levels as follows: concomitant prolonged-QTa and ECG-LVH, isolated prolonged-QTa, isolated ECG-LVH, and no ECG-LVH or prolonged-QTa (reference group). This approach aimed to examine whether there is an additive increased risk of mortality when prolonged-QTa and ECG-LVH coexist together when compared with what is observed when each is present in isolation. Second, we examined the risk of mortality associated with prolonged-QTa and ECG-LVH when entered separately in 2 separate sets of models, and then when both were entered in the same model as 2 separate variables (ie, adjusting for each other). This approach aimed to examine the attenuation of the magnitude of risk observed when the association between QT and risk of mortality is adjusted for ECG-LVH, and vice versa. In other words, this approach aimed to determine how much of the observed risk of mortality associated with ECG-LVH is explained (confounded) by prolonged-QTa. In both approaches, models were initially unadjusted (model 1), then adjusted for demographics (age, sex, and race; model 2), and then finally adjusted further for diabetes mellitus, hypertension, dyslipidemia, obesity, smoking status, history of cardiovascular disease (CVD; coronary heart disease, congestive heart failure, and stroke), QT-modifying drugs, and QRS duration. Interaction between ECG-LVH and prolonged-QTa as predictors for mortality was examined in the multivariable-adjusted model (model 3).
As additional analysis, we examined the association between different combinations of ECG-LVH and prolonged-QTa in subgroups of NHANES-III participants stratified by age (using 65 years as a cut point), sex, and race (whites versus nonwhites, hypertension, history of CVD, and obesity). The models were adjusted in a similar fashion to model 3 mentioned above. Other additional analysis included examining whether similar results will be obtained with other ECG-LVH criteria, such as Sokolow-Lyon.
All analyses were done using SAS 9.3 (SAS Institute Inc, Cary, NC). Statistical significance was determined as a 2-sided P<0.05.
Results
This analysis included 7506 participants (mean age, 59.4±13.3 years; 49% non-Hispanic whites; and 47% men). ECG-LVH was present in 4.2% (N=312) of the participants, of whom 16.4% had prolonged-QTa. The demographic-adjusted odds ratio for prolonged-QTa in those with ECG-LVH relative to those without ECG-LVH was 2.30 (95% confidence interval, 1.66-3.19). Prolonged-QTa was present in 7.0% (N=528) of the participants, of whom 9.7% had ECG-LVH. There was a weak correlation between Cornell voltage and QT interval (r=0.10; P<0.01). Table 1 shows characteristics of participants stratified by QT prolongation and ECG-LVH status. As shown, participants with both prolonged-QTa and ECG-LVH were more likely to be older, women, nonwhites, and have hypertension, diabetes mellitus, history of CVD, obesity, and prolonged QRS duration when compared with other groups, especially those without ECG-LVH or prolonged-QTa.
During a median follow-up of 13.8 years, 2569 deaths occurred at a rate of 26.9 deaths per 1000 person-years. The mortality rate was highest among participants with concomitant ECG-LVH and prolonged-QTa (58.2 deaths per 1000 person-years) and was the least among those without ECG-LVH or prolonged-QTa (24.8 deaths per 1000 person-years). However, the mortality rate was relatively similar in those with isolated ECG-LVH (47.7 deaths per 1000 person-years) and isolated prolonged-QTa (49.0 deaths per 1000 person-years; Figure 1 ). Figure 2 shows Kaplan-Meier survival curves for concomitant ECG-LVH and prolonged-QTa, isolated QT, and isolated ECG-LVH when compared with those for no ECG-LVH or prolonged-QTa. Table 2 shows the results of Cox proportional hazard analysis, where combinations of ECG-LVH and prolonged-QTa were used as a 4-level variable (concomitant ECG-LVH and prolonged-QTa, isolated ECG-LVH, isolated prolonged-QTa, and no ECG-LVH or prolonged-QTa [reference group]). When compared with no ECG-LVH or prolonged-QTa, concomitant ECG-LVH and prolonged-QTa was associated with 2.5× the risk of mortality, whereas isolated ECG-LVH and isolated prolonged-QTa were associated with approximately twice the risk (P<0.01 for all). After adjustment for demographics, CVD risk factors, and potential confounders, the risk of mortality remained the highest in the concomitant ECG-LVH and prolonged-QTa group (63% increased risk; P<0.01), followed by isolated ECG-LVH (48% increased risk; P<0.01), and then isolated prolonged-QTa hazard ratio (27% increased risk; P<0.01; Table 2 ). Similar direction of the results was observed when we examined the association between different combinations of ECG-LVH and prolonged-QTa with mortality in subgroups of NHANES-III participants stratified by age, sex, race, hypertension, history of CVD, and obesity with no significant interactions between the components of each subgroup (Table 3) . Also similar results were obtained when we used other ECG-LVH criteria, such as Sokolow-Lyon (results not shown). Table 4 shows the risk of mortality associated with each of ECG-LVH and prolonged-QTa using separate unadjusted and adjusted models. As shown, prolonged-QTa and ECG-LVH, entered separately in different sets of models, were associated with almost double the risk of mortality, which remained significantly high in the multivariable-adjusted models. More importantly, the strength of association between ECG-LVH and prolonged-QTa with mortality was not significantly attenuated when both were entered in the same model as 2 separate variables. As shown in Table 4 , the hazard ratio for ECG-LVH only attenuated from 1.46 to 1.44 after further adjustment for prolonged-QTa in the multivariable adjusted. In a similar model, the hazard ratio for prolonged-QTa only attenuated from 1.27 to 1.26 (Table 4) . There was no significant interaction between prolongedQTa and ECG-LVH as predictors for mortality (interaction P=0.489).
Discussion
We examined the inter-relationship between prolongedQTa and ECG-LVH using data from the NHANES-III, which enrolled a representative sample from the US general population.
Our study revealed 3 main findings. First, prolonged-QTa commonly coexists with ECG-LVH; ≈1 in 6 (16.4%) of our study participants with ECG-LVH had concomitant prolonged-QTa. Second, the magnitude of association between prolonged-QTa and mortality was not significantly attenuated after adjustment for ECG-LVH. Similarly, the magnitude of association between prolonged ECG-LVH and mortality was not significantly attenuated after adjustment for prolonged-QTa. These findings suggest that prolonged-QTa and ECG-LVH are 2 independent predictors of mortality, and the prognostic significance of one does not depend or explained by the other. Third, concomitant presence of prolonged-QTa and ECG-LVH carries a higher risk for mortality than the presence of each in isolation. This means that QT prolongation in the presence of ECG-LVH should not be considered as an innocent consequence of ECG-LVH, which is another finding supporting the independent prognostic information that could be obtained from each marker.
The relationship between LVH and prolonged-QT has a rational biological basis. In the hypertrophic myocardium, multiple pathological changes occur, such as myocardial fibrosis, myocyte hypertrophy, cell death, and disturbance in neurohormonal regulation. All of these pathological changes have an important effect on QT prolongation. 16 Studies in human patients and animal models have demonstrated that cardiac hypertrophy significantly affects myocardial cellto-cell coupling, leading to disturbances in action potential duration which subsequently can lead to potential malignant arrhythmia and sudden cardiac death. [21] [22] [23] [24] [25] This explains our results and the results from previous studies, showing that ECG-LVH is commonly associated with QT prolongation. [10] [11] [12] [13] [14] Other studies have also found that prolonged-QT in the setting of LVH denotes poor prognosis. In the Oregon Sudden Unexpected Death study, prolonged-QTa was significantly associated with sudden cardiac death in a case-control analysis using data from 158 subjects with ECG-LVH. 15 Similarly, QT prolongation was a predictor of mortality in patients with hypertension and ECG-LVH in the Losartan Intervention for End point Reduction in Hypertension (LIFE) Study. 26 Overall, Model adjusted for age, sex, race, diabetes mellitus, hypertension, dyslipidemia, obesity, smoking, history of cardiovascular disease, QT-modifying drugs, and QRS duration. ECG-LVH indicates ECG-left ventricular hypertrophy; QTa, heart-rate-adjusted QT interval; and reference group, no LVH or prolonged-QTa.
this is in agreement with our finding that LVH does not confound or interact with prolonged-QT as a predictor of death. Notably, the magnitude of risk in individuals with concomitant prolonged-QT and ECG-LVH in our study (63% increased risk in the fully adjusted model) was not much different than the sum of the risk associated with isolated prolonged-QT (27% increased risk) and isolated LVH (48% increased risk). This higher risk associated with concomitant prolonged-QTa and ECG-LVH when compared with each one in isolation also suggests the independence and the additive prognostic information that could be obtained from ECG-LVH and prolonged-QTa.
Our results should be read in the context of certain limitations. Sudden cardiac death is an adverse outcome that has been extensively examined in relationship to ECG-LVH and prolonged-QTa. Because sudden cardiac death is not ascertained in NHANES, we could not use as an outcome in our study. Nevertheless, this study is intended as a proof of concept; hence, a hard outcome, such as mortality, leaves little or no room for ascertainment bias. In contrast, a matter of debate has always been when an unexpected death should be called sudden and how the cardiac origin of the death should be ascertained. 27 This could cause significant misclassification that could risk the credibility of the results and its replication in other studies.
Another limitation of our study which stems from the design of NHANES-III is the lack of echocardiographic data, which could be used to obtain LV mass. However, our focus on the inter-relationship between QT prolongation and ECG-LVH is mainly from the perspective of electrophysiological remodeling occurring because of increased LV mass. Despite the low sensitivity of standard 12-lead ECG to detect anatomic ECG-LVH, it captures the electrophysiological remodeling subsequent to increased LV mass.
Despite these limitations, this report provides a comprehensive analysis of the inter-relationship between prolonged-QT and ECG-LVH as related but independent predictors of mortality and builds on the several strengths of the NHANES database. These strengths include the large sample size, the community-based and multiracial population, and well-ascertained covariates and outcome.
Conclusions
Prolonged-QT commonly coexists with ECG-LVH. However, both are totally independent and additive markers of poor prognosis. Hence, prolonged-QT in the setting of LVH should not be considered as an innocent consequence of LVH; instead both LVH and prolonged-QT should be evaluated and considered separately, despite their common concomitant coexistence. These findings could have potential applications in risk stratification and identifying individuals at high risk for poor outcomes.
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